Mercado de enfermedades renales: mapeo competitivo y perspectivas estratégicas para 2031

  • Report Code : TIPRE00014589
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 215
Buy Now

Se espera que el mercado de enfermedades renales alcance los 133.444,71 millones de dólares en 2027, frente a los 81.128,11 millones de dólares de 2019. Se estima que el mercado crecerá con una tasa compuesta anual del 6,5 % de 2020 a 2027.

  ;

Los formuladores de políticas deben garantizar que se implemente una combinación adecuada de opciones de políticas farmacéuticas para lograr un acceso equitativo, asequible y sostenible a los medicamentos, así como a la atención médica. La Organización Mundial de la Salud ha proyectado varias estrategias para ayudar a los responsables de la formulación de políticas a desarrollar políticas adecuadas, incluido el concepto de lista de medicamentos vitales y el enfoque de cobertura sanitaria universal (CSU). Además, los países europeos con sistemas avanzados de protección social y cobertura universal de salud han desarrollado sistemas de precios y reembolso de productos farmacéuticos que pretenden ofrecer diversos medicamentos cruciales a sus ciudadanos sin costo alguno o a un costo reducido. Por ejemplo, Armenia garantiza el reembolso del 100% de los medicamentos para enfermedades específicas como la tuberculosis, las enfermedades de salud mental, la diabetes y la insuficiencia renal crónica.

En mayo de 2019, VELTASSA, un medicamento recetado utilizado para tratar los niveles altos de potasio en la sangre (hiperpotasemia), obtuvo un reembolso en Alemania, tras la finalización del proceso AMNOG. (negociación de precios y proceso de arbitraje). Además, se obtuvo el reembolso del medicamento en Finlandia, Austria, Portugal, España y Bélgica y se recibió una recomendación favorable del Instituto Nacional para la Excelencia en la Salud y la Atención del Reino Unido. Además, a finales de 2019 se lanzó VELTASSA en Suecia, Noruega, Dinamarca, Bélgica, Alemania, España, Países Bajos y Austria. Además, en 2018, Vifor Pharma anunció un acuerdo de licencia con Zeria Pharmaceutical Co., Ltd. para catalizar el proceso de aprobación regulatoria y de reembolso de VELTASSA en Japón. Además, en diciembre de 2019, la Administración Nacional de Seguridad Sanitaria (NHSA) de China incluyó a Roxadustat en la Lista Nacional de Medicamentos de Reembolso (NRDL) actualizada. El medicamento Roxadustat está incluido en el NRDL para el tratamiento de la anemia en la ERC (enfermedad renal crónica). Es probable que estas lucrativas políticas de reembolso aceleren el crecimiento del mercado durante el período de pronóstico.

Mercados regionales lucrativos para la enfermedad renal


Perspectivas del mercado

Alta prevalencia de enfermedades crónicas que conducen a enfermedades renales

La enfermedad renal crónica (ERC) es una afección común y potencialmente mortal que afecta a 1 de cada 10 personas en todo el mundo. La presión arterial alta y la diabetes fueron las dos causas principales en el 75% de los casos de insuficiencia renal entre 2015 y 2017. Además, según un estudio publicado por la National Kidney Foundation en 2020, alrededor del 35,0% de la población diabética mayor de 20 años desarrollaría enfermedades crónicas. enfermedad renal durante el período de tiempo.

Según los datos publicados por National Kidney Foundation Inc., en 2020, es probable que la ERC cause más muertes que el cáncer de próstata o el cáncer de mama. Es una condición de salud de emergencia poco reconocida entre las personas. 1 de cada 3 adultos estadounidenses (alrededor de 80 millones de personas) está en riesgo debido a la ERC.

Según las estimaciones dadas por los Centros para el Control y la Prevención de Enfermedades (CDC) en En 2020, 1 de cada 3 adultos con diabetes y 1 de cada 5 adultos con presión arterial alta podrían tener enfermedad renal crónica. En 2015, 30,3 millones de personas en los EE. UU. tenían diabetes según la Asociación Estadounidense de Diabetes. Según los CDC, en 2014, alrededor de 118.000 personas en EE. UU. comenzaron el tratamiento para la enfermedad renal terminal, y se espera que el número de personas que toman este tratamiento aumente a medida que más personas tomen conciencia de esta afección. Además, los CDC afirman que alrededor del 96% de las personas con daños renales no son conscientes de que padecen una enfermedad renal crónica, lo que indica las perspectivas de mercado subyacentes en el mercado de las enfermedades renales. Se espera que estos factores mejoren el crecimiento del mercado durante el período de pronóstico.


Información sobre el tipo de producto

Según el tipo de producto, la enfermedad renal El mercado está segmentado en diagnóstico y tratamiento. En 2019, el segmento de diagnóstico representó la mayor parte del mercado. El crecimiento de este segmento se atribuye al aumento de los análisis de sangre, análisis de orina y diferentes procedimientos de imágenes.

Mercado global de enfermedades renales, por producto: 2019 y 2027


Información del usuario final

Basado en el usuario final, el mercado mundial de enfermedades renales se segmenta en hospitales, laboratorios de diagnóstico y otros. En 2019, el segmento de hospitales tuvo una participación importante en el mercado y se prevé que el mismo segmento registre la CAGR más alta del mercado durante el período de pronóstico.

Perspectivas estratégicas

Los lanzamientos y aprobaciones de productos son las estrategias comúnmente adoptadas por las empresas para expandir su presencia global y carteras de productos para satisfacer la creciente demanda de los consumidores. Los actores del mercado de enfermedades renales adoptan la estrategia de colaboración para ampliar su base de clientes en todo el mundo, lo que también les permite mantener su marca a nivel mundial.

Mercado de enfermedades renales: por tipo de producto

  •      Diagnóstico
    •     Análisis de sangre
    •     Análisis de orina
    •     Pruebas de Imagen
    •     Otros
  •   Tratamiento
    •   Clase de medicamento
      •   Inhibidores de la ECA
      •   Bloqueadores de los receptores de angiotensina II
      •   Diuréticos
      •   Otros

Mercado de enfermedades renales– por Usuario Final

  •      Hospitales
  •      Laboratorios de Diagnóstico
  •      Otros

Mercado de enfermedades renales: por Geografía

  • América del Norte
    • Estados Unidos
    • Canadá
    • México
  • < li>Europa
    • Francia
    • Alemania
    • Italia
    • Reino Unido
    • España
    • Resto de Europa
  • Asia Pacífico (APAC)
    • China
    • India
    • Corea del Sur
    • Japón
    • Australia
    • Resto de Asia Pacífico
  • Medio Oriente y África (MEA)
      < li>Sudáfrica
    • Arabia Saudita
    • EAU
    • Resto de Medio Oriente y África
  • América del Sur y Central
    • Brasil
    • Argentina
    • Resto de América del Sur

  ;

Perfiles de empresas

  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • AbbVie's Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Sysmex Corp.
  • Fresenius Medical Care SE & Co. KGaA
  • Siemens Healthineers AG
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is kidney disease?

Renal disease, commonly known as chronic kidney failure, is characterised by a progressive loss of kidney function. Wastes and excess fluids are removed from the circulation by the kidneys, which are then excreted in urine. Advanced chronic renal disease can result in harmful accumulations of fluid, electrolytes, and wastes in the body. These issues may develop gradually over a lengthy period of time. Diabetes, high blood pressure, and other illnesses can lead to chronic kidney disease. Early detection and treatment can typically prevent the progression of chronic renal disease. When kidney disease continues, it can lead to renal failure, which necessitates dialysis or a kidney transplant. Chronic renal disease treatment focuses on delaying the progression of kidney damage, usually by addressing the underlying cause. Controlling the cause, however, may not be enough to prevent kidney disease from developing. Without mechanical filtering (dialysis) or a kidney transplant, chronic kidney disease can proceed to end-stage kidney failure, which is fatal.

What are the driving factors for the kidney diseases market across the globe?

Key factors that are driving the growth of this market are high prevalence of chronic diseases leading to kidney diseases and favorable reimbursement policy for kidney disease treatments are expected to boost the market growth for the kidney diseases over the years.

What is the market CAGR value of kidney diseases market during forecast period?

The CAGR value of the kidney diseases market during the forecasted period of 2020-2027 is 6.5%.

Which product type led the kidney diseases market?

The diagnosis segment held the largest share of the market in the global kidney diseases market and held the largest market share of 56.80% in 2019.

Which end user held the largest share in the kidney diseases market?

The hospitals segment dominated the global kidney diseases market and held the largest market share of 47.35% in 2019.

Who are the key players in the kidney diseases market?

The kidney diseases market majorly consists of the players such as Abbott, Siemens AG, Amgen Inc., Sysmex Corporation, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd, Fresenius Medical Care, F. Hoffmann-La Roche Ltd, AbbVie Inc., and Pfizer among others.

The List of Companies - Kidney Disease Market

  1. Abbott
  2. F. Hoffmann-La Roche Ltd.
  3. AbbVie's Inc.
  4. Pfizer Inc.
  5. Teva Pharmaceutical Industries Ltd.
  6. GlaxoSmithKline plc
  7. Amgen Inc.
  8. Sysmex Corp.
  9. Fresenius Medical Care SE & Co. KGaA
  10. Siemens Healthineers AG

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports